Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054

Alexander Eggermont; Michal Kicinski; Stefan Suciu

doi:10.1136/jitc-2021-004272

Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054

Alexander Eggermont, Michal Kicinski, Stefan Suciu

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

3 Citaten (Scopus)

Originele taal-2	Engels
Artikelnummer	e004272
Tijdschrift	Journal for ImmunoTherapy of Cancer
Volume	10
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1136/jitc-2021-004272
Status	Gepubliceerd - 18 jan. 2022
Extern gepubliceerd	Ja

Toegang tot document

10.1136/jitc-2021-004272

Citeer dit

@article{9d585daa9d3948d9a80565c6c63404e9,

title = "Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054",

keywords = "adjuvants, autoimmunity, immunologic, immunotherapy, melanoma",

author = "Alexander Eggermont and Michal Kicinski and Stefan Suciu",

note = "Funding Information: Competing interests AE reports receiving personal fees from Biocad, BioInvent, BioNTech, BMS, CatalYm, Ellipses, GSK, IO Biotech, ISA Pharmaceuticals, Merck/ MSD, Nektar, Novartis, Pfizer, SAiRoPA, Sellas, SkylineDx, TigaTx, TTxDiscovery and owning equity in SkylineDx and SAiRoPA. MK reports receiving grants from Merck, BMS, and Pierre-Fabre. SS reports receiving grants from Merck, BMS, and Pierre-Fabre.",

year = "2022",

month = jan,

day = "18",

doi = "10.1136/jitc-2021-004272",

language = "English",

volume = "10",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054

AU - Eggermont, Alexander

AU - Kicinski, Michal

AU - Suciu, Stefan

N1 - Funding Information: Competing interests AE reports receiving personal fees from Biocad, BioInvent, BioNTech, BMS, CatalYm, Ellipses, GSK, IO Biotech, ISA Pharmaceuticals, Merck/ MSD, Nektar, Novartis, Pfizer, SAiRoPA, Sellas, SkylineDx, TigaTx, TTxDiscovery and owning equity in SkylineDx and SAiRoPA. MK reports receiving grants from Merck, BMS, and Pierre-Fabre. SS reports receiving grants from Merck, BMS, and Pierre-Fabre.

PY - 2022/1/18

Y1 - 2022/1/18

KW - adjuvants

KW - autoimmunity

KW - immunologic

KW - immunotherapy

KW - melanoma

UR - https://www.scopus.com/pages/publications/85123675200

U2 - 10.1136/jitc-2021-004272

DO - 10.1136/jitc-2021-004272

M3 - Article

C2 - 35042824

AN - SCOPUS:85123675200

SN - 2051-1426

VL - 10

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 1

M1 - e004272

ER -